

SEP 10 2008

PTO/SB/08 (09-06)

Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Transmittal Form for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: September 10, 2008

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number 10/734,644
Filing Date 12/15/2003
First Named Inventor Jay BUA
Art Unit 1642
Examiner Name B. Fetterolf
Attorney Docket Number 029488-0112

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (If known)	MM-DD-YYYY		
/B.F./	A1	US-2004/0086552	5/6/2004	KLOKKERS ET AL.	
	A2	US-5,613,958	3/25/1997	KOCHINKE ET AL.	
	A3	US-4,973,755	11/27/1990	GRAFE ET AL.	
	A4	US-5,720,963	2/24/1998	SMITH	
	A5	US-6,013,270	1/11/2000	HARGRAVES ET AL.	
	A6	US-2003/0087885	5/8/2003	MASINI-ETEVE ET AL.	
	A7	US-6,503,894	1/7/2003	DUDLEY ET AL.	
	A8	US-2005/0031695 A1	2/10/2005	ROUANET ET AL.	
	A9	US-2005/0032909 A1	2/10/2005	LIGNIERES ET AL.	
	A10	US-2005/0032910 A1	2/10/2005	PALUMBO ET AL.	
	A11	US-2005/0158388 A1	7/21/2005	LE NESTOUR ET AL.	
	A12	US-2005/0208139 A1	9/22/2005	HILT ET AL.	
	A13	US-2005/0209340 A1	9/22/2005	LE NESTOUR	
	A14	US-2006/0105041 A1	5/18/2006	MASINI-ETEVF	

UNPUBLISHED U.S. PATENT APPLICATION DOCUMENTS

Examiner Initials*	Cite No.†	U.S. Patent Application Document	Filing Date of Cited Document MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Serial Number-Kind Code* (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code* Number* Kind Code ² (if known)					
/B.F./	A15	EP-513 832		11/12/1992	BRISTOL-MYERS SQUIBB COMPANY		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
/B.F./	A16	Office Action issued May 29, 2008, in U.S. Application 10/734,640, 19 pages. 10/734, 640	

Examiner Signature	/Brandon Fetterolf/	Date Considered	11/12/2008
--------------------	---------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, 1450, Alexandria, VA 22315-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number 10/734,644	
Date Submitted: September 10, 2008		Filing Date 12/15/2003	
(use as many sheets as necessary)		First Named Inventor Jay BUA	
		Art Unit 1642	
		Examiner Name B. Fetterolf	
Sheet	2	Attorney Docket Number	029488-0112

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
/B.F./	A17	Notice of Allowance issued June 13, 2008, in U.S. Application 10/734,638, 11 pages.	
↓	A18	Ruland et al.; "Influence of Various Penetration Enhancers on the In Vitro Permeation of Amino Acids Across Hairless Mouse Skin"; 1992, International Journal of Pharmaceutics, vol. 85, no. 1-3, pp. 7-17 (Abstract only)	
	A19	Friend et al.; "Simply Alkyl Esters as Skin Permeation Enhancers", 1989, Journal of Controlled Release, vol. 9, no. 1 pp. 33-41 (Abstract only)	
	A20	Santoyo et al.; "Penetration Enhancer Effects on the In Vitro Percutaneous Absorption of Piroxicam Through Rat Skin" 1995; 117: 219-224.	
↓	A21	MALET, Catherine et al.; "Effect of 4-hydroxytamoxifen isomers on growth and ultrastructural aspects of normal human breast epithelial (HBE) cells in culture"; Journal of Steroid Biochemistry & Molecular Biology, 82 (2002), pp. 289-296	
/B.F./	A22	MURPHY, C. S. et al.; "Structure-Function Relationships of Hydroxylated Metabolites of Tamoxifen that Control the Proliferation of Estrogen-Responsive T47D Breast Cancer Cells In Vitro; Molecular Pharmacology 38:737-743 (1990).	

Examiner Signature	/Brandon Fetterolf/	Date Considered	11/12/2008
---------------------------	---------------------	------------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.